Treatment of Advanced Hodgkin's Disease: EBVD versus Intensive Brief Chemotherapy

We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia & lymphoma 2003-08, Vol.44 (8), p.1361-1365
Main Authors: Avilés, Agustin, Cleto, Sergio, Neri, Natividad, Huerta-Guzmán, Judith, Talavera, Alejandra, Castañeda, Claudia, González, Martha
Format: Article
Language:English
Subjects:
Actuarial Analysis
Acute Toxicity
Adjuvant Radiotherapy
Adult
Aged
Agranulocytosis - chemically induced
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - toxicity
Bleomycin
Bleomycin - administration & dosage
Chemotherapy
Dacarbazine - administration & dosage
Epirubicin
Epirubicin - administration & dosage
Female
Hodgkin Disease - complications
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Hodgkin's Disease
Humans
Infection - chemically induced
Male
Middle Aged
Survival Analysis
Treatment Outcome
Vinblastine - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We start a controlled clinical trial to assess efficacy and toxicity of EBVD (epirubicin, bleomycin, vinblastine and dacarbazine) with an intensive and brief program of seven drugs administered weekly for 12 weeks in previously untreated patients with advanced Hodgkin's disease. Two hundred and sixty four patients were randomized to receive EBVD chemotherapy (134 cases) or intensive chemotherapy (130 cases). Eligible patients were either previously untreated stages III or IV. Patients with bulky disease received adjuvant radiotherapy. In an intent to treat analysis, all patients were evaluable for efficacy and toxicity. Complete response rate to the two regimens were similar (88 and 84%, respectively). However, actuarial 5 years overall survival rates were 87% (95% confidence interval (CI): 78-94%) for the EBVD regimen, which is statistically different to 59% (95% CI: 48-66%) for the intensive program ( p
ISSN:1042-8194
1029-2403
DOI:10.1080/1042819031000067729